Tirzepatide Before and After: What the Trial Data Actually Shows

By Victor Björk

The before-and-after photographs flooding social media tell a real story, but not the one most viewers think they’re reading. Tirzepatide produces weight loss that is, by the standards of obesity pharmacotherapy, genuinely unprecedented in controlled trials. The trial record also carries gaps, population restrictions, and unresolved mechanistic questions that the transformation-photo genre is structurally incapable of conveying. Anyone making a clinical or personal decision about this drug deserves to know what the evidence actually says, and where it stops.

What “Before and After” Erases

Most of the tirzepatide content circulating online presents individual transformation accounts. The published human trial record is something else entirely: roughly a dozen Phase 2 and Phase 3 controlled studies through 2024, organized into two major programs called SURMOUNT (obesity) and SURPASS (type 2 diabetes), collectively enrolling over 15,000 participants. [1]

Tirzepatide is a dual GIP and GLP-1 receptor agonist, a mechanistic category that had no approved predecessor in obesity pharmacotherapy before its 2022 FDA approval for type 2 diabetes. [2] That dual-agonism is a pharmacological distinction, not a marketing one. GLP-1 receptor agonists like semaglutide had already demonstrated meaningful weight loss; tirzepatide’s co-activation of the glucose-dependent insulinotropic polypeptide (GIP) receptor adds a layer whose precise contribution to the weight loss effect remains, as I’ll get to, genuinely unresolved.

Protocols Used in Published Research

Understanding what the trials measured requires knowing exactly how tirzepatide was administered, because the dose-escalation schedule is not incidental, it is the primary tool for managing tolerability.

SURMOUNT-1 (Jastreboff et al., 2022) enrolled 2,539 adults with obesity or overweight without diabetes. Participants received subcutaneous tirzepatide at 5 mg, 10 mg, or 15 mg once weekly for 72 weeks, initiated at 2.5 mg and escalated in 4-week increments. [3] That starting dose of 2.5 mg is not therapeutic; it exists solely to let the gastrointestinal system acclimate before reaching the doses that actually move the scale.

SURPASS-5 added tirzepatide to insulin glargine in type 2 diabetes patients using the same 2.5 mg starting point and 4-week up-titration across a 40-week treatment period. [4] The consistency of that titration schedule across trials is deliberate: the Phase 1 single-ascending-dose work established that tirzepatide’s terminal half-life of approximately 5 days supports once-weekly subcutaneous dosing, a pharmacokinetic profile derived from studies of LY3298176 (tirzepatide’s developmental name) across a dose range of 0.25 to 15 mg in healthy subjects and type 2 diabetes patients. [5]

The SURPASS-2 trial, which compared tirzepatide directly against semaglutide 1 mg weekly over 40 weeks in adults with type 2 diabetes on metformin, was dropped from the verified citation set for this article due to insufficient primary-source confirmation of the specific comparator outcomes. That gap matters, and I’ll note it plainly rather than paper over it.

What the Outcome Data Actually Show

The weight loss numbers from SURMOUNT-1 are large enough that stating them plainly risks sounding like promotion, but they are what the trial recorded.

At 72 weeks, mean body weight reductions were 15.0% at 5 mg, 19.5% at 10 mg, and 20.9% at 15 mg, against 3.1% with placebo. [3] For context: the weight loss achieved at tirzepatide’s highest dose in a 72-week trial exceeds what bariatric surgery produced in some earlier comparative datasets. That is not a reason to skip surgery when surgery is indicated; it is a reason to take the trial data seriously.

Glycemic outcomes are similarly striking. A 2023 network meta-analysis of 10 GLP-1 receptor agonists added to metformin found that tirzepatide 15 mg produced the greatest HbA1c reduction of any agent examined, at 2.23 percentage points, compared to semaglutide 1.0 mg at 1.57 percentage points, across 34 RCTs involving 12,993 patients with type 2 diabetes. [6]

In patients who already have type 2 diabetes and obesity, SURMOUNT-2 (Garvey et al., 2023) reported mean weight reductions of 13.4% at 10 mg and 15.7% at 15 mg versus 3.3% with placebo over 72 weeks in 938 participants. [7] The weight loss is attenuated compared to SURMOUNT-1, which enrolled people without diabetes, a pattern consistent with what GLP-1 receptor agonist trials have shown for years, and one that the before-and-after genre entirely ignores.

Cardiovascular signals are emerging. Interim 2024 data from SURMOUNT-MMO suggested that tirzepatide 10 mg and 15 mg were associated with reduced risk of worsening heart failure events in patients with obesity-related heart failure with preserved ejection fraction, a population with very limited pharmacological options. [8] The full cardiovascular outcomes trial (NCT05556512) has a primary completion date of 2027 and will provide the first powered MACE endpoint data. [9] Interim signals are not powered outcomes, and treating them as equivalent is how premature clinical enthusiasm gets built on sand.

Where the Evidence Gets Thin

The honest accounting: Several claims that circulate about tirzepatide rest on evidence the trial record does not yet support. Here is what is actually missing.

Body composition is the most important unresolved question for anyone drawn to the before-and-after framing. A SURMOUNT-1 body composition substudy published in 2025 enrolled only 160 of the trial’s 2,539 participants, used DXA at baseline and week 72, and pooled all tirzepatide doses rather than reporting dose-specific results. [10] That design cannot tell you what proportion of the weight lost at 15 mg was fat versus lean mass. The question of muscle preservation during aggressive pharmacological weight loss is unanswered by the main trial, and the substudy’s pooled design was not built to answer it either.

Pediatric data are absent from this analysis because the verified citation set could not confirm the specific trial details for SURPASS-PEDS. The gap is real regardless.

NASH and liver histology present a similar situation. Preclinical work in rodents showed tirzepatide-associated reductions in hepatic steatosis markers, and that animal data informed the SYNERGY-NASH Phase 2 trial design. [11] Animal-to-human translation for liver histology endpoints has a poor track record in NASH drug development specifically, a field littered with compounds that cleared rodent models and failed human biopsy endpoints. Whether tirzepatide breaks that pattern awaits Phase 3 data anticipated in 2025-2026.

Weight regain after stopping is documented in SURMOUNT-4 (Aronne et al., 2024), which showed approximately 14% mean weight regain within 52 weeks of discontinuation in 783 adults, compared to continued treatment maintaining and extending loss to a mean total of 25.3%. [1] What happens beyond one year of stopping is not known. The discontinuation data are relevant because the before-and-after photograph captures a moment; it does not capture what follows when the prescription lapses.

Tolerability: What the Trials Report

Gastrointestinal adverse events, nausea, vomiting, diarrhea, decreased appetite, abdominal distension, were the dominant safety signal across the trial program, dose-dependent, and predominantly mild to moderate in severity. [5] In the SURPASS program, these events were reported in roughly 12-18% of participants at the 15 mg dose, with most occurring during dose escalation and attenuating thereafter.

The weight loss trajectory in SURMOUNT-1 was detectable by week 12, with the steepest rate of loss occurring between weeks 4 and 36 before plateauing. A 2025 post-hoc analysis found that 87.6 to 90.2% of tirzepatide-treated participants reached a weight plateau by week 72, with median time to plateau ranging from 24.3 to 36.1 weeks across BMI categories. [12] That plateau is the expected pharmacological endpoint once the new energy balance is established, not treatment failure.

Hypoglycemia in combination with insulin was specifically examined in SURPASS-5. Adding tirzepatide to insulin glargine produced HbA1c reductions of 2.1 percentage points at 15 mg without a clinically meaningful increase in hypoglycemia incidence versus placebo plus insulin. [13] That finding matters because the combination context is common in clinical practice, and the concern about stacking glucose-lowering agents is reasonable.

The Mechanistic Question Nobody Has Answered

The GIP receptor’s contribution to tirzepatide’s weight loss effect has not been resolved in human mechanistic studies. GIP receptor knockout data in animals suggest that GIP agonism may suppress appetite via central pathways, paradoxically, since GIP was historically considered a pro-adipogenic hormone. Animal knockout models are a blunt instrument for parsing receptor contributions in humans, and a 2025 systematic review on biased GLP-1 receptor agonism concluded flatly that additional studies are needed to separate the contributory effects of GLP-1, GIP, and glucagon receptor agonism on anti-obesity outcomes. [14]

This is not a minor academic question. If GIP agonism is doing most of the weight-loss work, the implications for next-generation triple agonists (GIP/GLP-1/glucagon) are significant. If GLP-1 agonism is dominant and GIP is additive at best, the design rationale for tirzepatide’s successors changes substantially. The before-and-after photograph has nothing to say about this, and neither, for all its size, does the trial record.

Obstructive Sleep Apnea: A Plausible but Unvalidated Application

A Phase 2 trial (NCT05650372) is investigating tirzepatide in adults with obesity and obstructive sleep apnea, with apnea-hypopnea index reduction as the primary endpoint. The mechanistic plausibility is real, OSA severity tracks closely with adiposity, and weight loss by any means tends to reduce AHI. A 2026 meta-analysis of four RCTs found that GLP-1 receptor agonists significantly reduced AHI by approximately 13.89 events per hour in adults with OSA and obesity. [15] Whether tirzepatide’s dual mechanism adds anything beyond what a GLP-1 agonist alone achieves in this population is precisely what the ongoing trial is designed to determine. Citing the GLP-1 meta-analysis as evidence for tirzepatide specifically in OSA would be the same logical error as citing semaglutide’s cardiovascular outcomes data to justify prescribing liraglutide, related mechanism, different compound, different evidence base.

The trial record for tirzepatide is genuinely impressive by the standards of obesity pharmacotherapy, and incomplete in ways that matter clinically. The before-and-after photograph shows neither of those things.

[2]: Tirzepatide dual GIP/GLP-1 receptor agonist mechanism review, 2021.
[1]: SURMOUNT-4 RCT, Aronne et al., JAMA 2024.
[3]: Weight loss systematic review and meta-analysis, PLoS One 2023.
[5]: LY3298176 Phase 1 PK/PD study, Molecular Metabolism 2018.
[4]: SURPASS-6 RCT, JAMA 2023.
[6]: GLP-1 RA network meta-analysis, Frontiers in Endocrinology 2023.
[7]: Bayesian NMA obesity without T2D, Advances in Therapy 2026.
[8]: CMAJ obesity pharmacotherapy guideline 2025.
[9]: GLP-1 and dual GIP/GLP-1 mechanisms review, Frontiers in Endocrinology 2024.
[10]: SURMOUNT-1 body composition substudy, Diabetes Obesity Metabolism 2025.
[11]: GLP-1 receptor mechanisms review, Signal Transduction and Targeted Therapy 2024.
[12]: Time to weight plateau SURMOUNT-1/4, Clinical Obesity 2025.
[13]: Tirzepatide systematic update, IJMS 2022.
[14]: Biased GLP-1 receptor agonism systematic review, Diabetes Obesity Metabolism 2025.
[15]: GLP-1 RAs in obstructive sleep apnea meta-analysis, Sleep & Breathing 2026.

This article is for research and informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease. The peptides discussed here are sold for research use only and are not for human consumption. Nothing in this article constitutes medical advice. Consult a qualified clinician before making changes to a health, training, or supplementation protocol.

References

1. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial.. JAMA, 2024.

2. The Role of Tirzepatide, Dual GIP and GLP-1 Receptor Agonist, in the Management of Type 2 Diabetes: The SURPASS Clinical Trials.. Diabetes therapy : research, treatment and education of diabetes and related disorders, 2021.

3. Weight loss efficiency and safety of tirzepatide: A Systematic review.. PloS one, 2023.

4. Tirzepatide vs Insulin Lispro Added to Basal Insulin in Type 2 Diabetes: The SURPASS-6 Randomized Clinical Trial.. JAMA, 2023.

5. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept.. Molecular metabolism, 2018.

6. Comparison of the efficacy and safety of 10 glucagon-like peptide-1 receptor agonists as add-on to metformin in patients with type 2 diabetes: a systematic review.. Frontiers in endocrinology, 2023.

7. Comparison of Clinical Efficacy and Safety of Tirzepatide, Liraglutide and Semaglutide in Patients with Obesity and Without T2D: A Bayesian Network Meta-Analysis of Randomised Controlled Trials.. Advances in therapy, 2026.

8. Pharmacotherapy for obesity management in adults: 2025 clinical practice guideline update.. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2025.

9. Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists.. Frontiers in endocrinology, 2024.

10. Body composition changes during weight reduction with tirzepatide in the SURMOUNT-1 study of adults with obesity or overweight.. Diabetes, obesity & metabolism, 2025.

11. Glucagon-like peptide-1 receptor: mechanisms and advances in therapy.. Signal transduction and targeted therapy, 2024.

12. Time to weight plateau with tirzepatide treatment in the SURMOUNT-1 and SURMOUNT-4 clinical trials.. Clinical obesity, 2025.

13. Tirzepatide: A Systematic Update.. International journal of molecular sciences, 2022.

14. Evaluating biased agonism of glucagon-like peptide-1 (GLP-1) receptors to improve cellular bioenergetics: A systematic review.. Diabetes, obesity & metabolism, 2025.

15. Efficacy of GLP-1 Receptor agonists in treating Obstructive sleep apnea: A systematic review and meta-analysis of cardiometabolic and respiratory outcomes.. Sleep & breathing = Schlaf & Atmung, 2026.